Shares in Artrya Limited (ASX:AYA) declined 12.16% to A$3.25 on 5 October 2026. Trading in any individual session can be influenced by a range of factors including broader market conditions, investor sentiment and positioning, and does not necessarily reflect a single cause.

Company Update

Against the backdrop of the day's trading, an announcement from Artrya Limited (ASX:AYA), released on 2 October 2026, was relevant context for investors tracking the company. Artrya disclosed that it had signed a five-year commercial agreement with Huntsville Hospital Health System (HH Health) for its Salix® AI-powered cloud platform, making HH Health the company's fourth U.S. commercial customer and the first SAPPHIRE Study participant to convert to a commercial arrangement.

Business Model and Operational Footprint

Artrya Limited is an Australian-listed medical technology company commercialising the Salix® AI platform for the real-time, point-of-care assessment and management of coronary artery disease. The platform operates as a cloud-based system integrated into clinical workflows at hospitals and health systems.

Salix® comprises multiple modules: Salix® Coronary Anatomy, which is commercially available and FDA-cleared; Salix® Coronary Plaque, which generates fee-per-scan Revenue from CCTA assessments; and Salix® Coronary Flow, which is pending FDA clearance. The company operates a SAPPHIRE Study network designed to establish clinical engagement with major U.S. cardiovascular centres as a pathway toward commercial adoption.

Sector Context

Coronary artery disease remains the leading cause of death globally. The adoption of AI-assisted diagnostic tools in cardiology is an active area of clinical and commercial development, with FDA clearance representing a critical gateway for medical technology companies seeking U.S. market access. CCTA-based non-invasive cardiac imaging has grown in clinical use, and software platforms that enhance its diagnostic Utility are increasingly being evaluated by major health systems.

Converting clinical research relationships into long-term commercial contracts is a core challenge for medical AI companies. Enterprise-scale deployments across multi-hospital networks represent a significant commercial milestone in this sector.

The Announcement

The 2 October 2026 announcement confirmed that Artrya had signed a five-year commercial agreement with HH Health, a 15-hospital network. The minimum contracted value under the agreement is US$0.5 million for Salix® Coronary Anatomy, which generates recurring SaaS subscription revenue. Additional fee-per-scan revenue is expected from Salix® Coronary Plaque, and from Salix® Coronary Flow once FDA clearance is obtained. The US$0.5 million minimum relates only to the Coronary Anatomy module and does not include potential revenue from the Plaque and Flow modules.

HH Health is described as Artrya's largest U.S. customer deployment to date, with Salix® to be integrated across applicable clinical workflows within the broader health system. The agreement represents the first commercial conversion from the SAPPHIRE Study network, validating the company's clinical-to-commercial strategy. Artrya's other U.S. commercial customers are Tanner Health, Northeast Georgia Health System and Cone Health.

Growth Catalysts

The SAPPHIRE Study network provides a pipeline of potential commercial conversions from clinical research participants, and the HH Health agreement demonstrates that this pathway is functioning. Enterprise-scale deployment across a 15-hospital system establishes a reference site that may support future commercial discussions. The multi-module revenue model, combining SaaS subscriptions with usage-based charges, creates potential for revenue growth as clinical adoption deepens. Progression of Salix® Coronary Flow through FDA clearance would add a further revenue stream.

Risks

The minimum contracted value of US$0.5 million for Salix® Coronary Anatomy is modest relative to a five-year term; actual revenue will depend on clinical utilisation levels across HH Health's network. Revenue from the Plaque and Flow modules is subject to adoption within the agreement and, for the Flow module, FDA clearance which has not yet been obtained. Converting remaining SAPPHIRE participants to commercial customers is not guaranteed. Competition in AI-assisted cardiac imaging is growing, and regulatory approval timelines are inherently uncertain.